| Literature DB >> 30700709 |
José Villar1,2, Michelle Fernandes3,4, Manorama Purwar5, Eleonora Staines-Urias3, Paola Di Nicola6, Leila Cheikh Ismail7, Roseline Ochieng8, Fernando Barros9, Elaine Albernaz10, Cesar Victora11, Naina Kunnawar5, Sophie Temple3, Francesca Giuliani6, Tamsin Sandells3, Maria Carvalho8, Eric Ohuma3,12, Yasmin Jaffer13, Alison Noble14, Michael Gravett15, Ruyan Pang16, Ann Lambert3, Enrico Bertino17, Aris Papageorghiou3,18, Cutberto Garza19, Alan Stein20, Zulfiqar Bhutta21, Stephen Kennedy3,18.
Abstract
It is unclear whether early child development is, like skeletal growth, similar across diverse regions with adequate health and nutrition. We prospectively assessed 1307 healthy, well-nourished 2-year-old children of educated mothers, enrolled in early pregnancy from urban areas without major socioeconomic or environmental constraints, in Brazil, India, Italy, Kenya and UK. We used a specially developed psychometric tool, WHO motor milestones and visual tests. Similarities across sites were measured using variance components analysis and standardised site differences (SSD). In 14 of the 16 domains, the percentage of total variance explained by between-site differences ranged from 1.3% (cognitive score) to 9.2% (behaviour score). Of the 80 SSD comparisons, only six were >±0.50 units of the pooled SD for the corresponding item. The sequence and timing of attainment of neurodevelopmental milestones and associated behaviours in early childhood are, therefore, likely innate and universal, as long as nutritional and health needs are met.Entities:
Mesh:
Year: 2019 PMID: 30700709 PMCID: PMC6353986 DOI: 10.1038/s41467-018-07983-4
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Participant flow: INTERGROWTH-21st Project Neurodevelopment Assessment cohort at 2 years of age
Neonatal characteristics of children included in the INTERGROWTH-21st Neurodevelopment Assessment Study compared to children lost to follow-up
| Children evaluated ( | Children lost to follow-up ( | |
|---|---|---|
| Gestational age at delivery, weeks | 39.4 (1.5) | 39.3 (1.5) |
| Birthweight, kg | 3.2 (0.5) | 3.2 (0.5) |
| Birth length, cm | 49.0 (2.0) | 49.0 (2.1) |
| Head circumference at birth, cm | 33.9 (1.4) | 34.0 (1.3) |
| Apgar at 5 min | 9.5 (0.6) | 9.6 (0.7) |
| Age at hospital discharge, daysa | 3.0 (2.0, 4.0) | 2.0 (1.0, 3.0) |
| Boys | 624 (47.7) | 160 (48.3) |
| Preterm birth (<37 weeks’ gestation by LMP) | 54 (4.1) | 16 (4.8) |
| Early preterm (<34 weeks’ gestation by LMP) | 6 (0.5) | 2 (0.6) |
| NICU stay > 1 day; <3 days | 47 (3.6) | 18 (5.5) |
| NICU > 3 days | 33 (2.5) | 12 (3.6) |
| Hyperbilirubinaemia | 66 (5.1) | 18 (5.5) |
| Respiratory distress syndrome | 29 (2.2) | 7 (2.1) |
| Transient tachypnoea of the newborn | 18 (1.4) | 12 (3.6) |
| Exclusive breastfeeding at hospital discharge | 1209 (92.6) | 300 (90.9) |
Data are means (SD) or proportions (%) unless otherwise specified. Missing data below 2% for all variables
LMP last menstrual period, NICU neonatal intensive care unit
aMedian (inter-quartile range)
Morbidity diagnoses between 1 and 2 years of life of children included in the INTERGROWTH-21st Neurodevelopment Assessment Study
| Children in the analysis ( | |
|---|---|
| Hospitalised at least once | 117 (9.0) |
| Any prescription made by a health-care practitioner: | 771 (59.0) |
| • Antibiotics (≥3 regimens) | 163 (12.5) |
| •Iron/folic acid/vitamin B12/other vitamins (≥3 regimens) | 216 (16.5) |
| Up-to-date with local vaccination policies | 1231 (94.3) |
| Otitis media/Pneumonia/Bronchiolitis | 98 (7.5) |
| Parasitosis/Diarrhoea/Vomiting | 51 (3.9) |
| Exanthema/skin disease | 159 (12.2) |
| Urinary tract infection/pyelonephritis | 6 (0.5) |
| Fever ≥ 3 days (≥3 episodes) | 147 (11.3) |
| Other infections requiring antibiotics | 44 (3.4) |
| Asthma | 15 (1.1) |
| Gastro-oesophageal reflux | 4 (0.3) |
| Cow’s milk protein allergy | 11 (0.8) |
| Food allergies | 15 (1.1) |
| Injury trauma | 34 (2.6) |
| Surgery | 9 (0.7) |
Data are number (%). Missing data below 1% for all variables
aFor five children, information on morbidities in the first year of life was used
Variance components analysis for individual domains of the INTERGROWTH-21st Neurodevelopment Assessment Package showing variance between study sites as % of the total variance
| Neurodevelopment domain | Model with age and sex ( | Model with age, sex and fetal HC ( | Model with age, sex, HC and length at 2 years ( |
|---|---|---|---|
| Cognitive score (%)a | 1.3 | 1.2 | 1.2 |
| Executive function-like (%)a | 3.4 | 3.3 | 3.3 |
| Attentional problems score (%)b | 5.4 | 5.8 | 4.1 |
| Visual acuity (%)a | 8.0 | 6.9 | 7.4 |
| Visual contrast sensitivity (%)a | 7.3 | 7.3 | 6.9 |
| Fine motor score (%)a | 6.0 | 6.0 | 6.2 |
| Gross motor score (%)b,c | 6.5 | 7.2 | 6.7 |
| Receptive language score (%)b,c | 1.9 | 1.4 | 1.9 |
| Expressive language score (%)b,c | 7.3 | 7.0 | 7.3 |
| Positive behaviour score (%)c | 8.5 | 8.2 | 8.7 |
| Negative behaviour score (%)c | 14.1 | 13.6 | 13.7 |
| Total behaviour score (%)c | 9.2 | 9.2 | 9.9 |
| Emotional reactivity score (%)b | 14.2 | 15.3 | 14.0 |
| Positive affect score (%)b | 2.5 | 2.7 | 2.7 |
| Age when first stood alone (%)b | 5.6 | 5.3 | 6.5 |
| Age when first walked alone (%)b | 6.9 | 6.9 | 7.6 |
Variance components estimated by nonparametric generalised linear mixed models including covariates as fixed effects and study site as random effect
Age age at assessment, fetal HC ultrasound head circumference z-score from 26 to 34 weeks’ gestation compared to the INTERGROWTH-21st Fetal Growth Standards[2]; Head circumference and length z-scores at 2 years compared to the WHO Child Growth Standards[8]
aDirect administration
bCaregiver report
cConcurrent observation
Fig. 2Standardised site difference for mean scores of individual domains of the INTERGROWTH-21st Project Neurodevelopment Assessment, Cardiff tests and age of achievement of two WHO gross motor development milestones. The standardised site differences calculated as the site mean of each domain minus the mean for all sites combined divided by the SD of all sites together, adjusted by the age at the time of assessment and sex. Results are shown as: Brazil (green), India (yellow), Kenya (brown), UK (blue) and Italy (red). Sample size according to domain and study site is given in Supplementary Table 2
Fig. 3Variance components analysis of 16 neurodevelopmental domains evaluated in the present study (upper part) and variance components analysis of 7 measures of fetal, newborn, infant and child growth (lower part). Red bars are the % of total variance explained by between sites variability for each domain or growth measure. Data for the seven growth measures: INTERGROWTH-21st Project (eight study sites)[2,3,5,9]; WHO Multicentre Growth Reference Study (five study sites)[8]; Habicht et al.[41]